Immunogenicity of Moraxella catarrhalis vaccine candidates in children

Information

  • Research Project
  • 8969634
  • ApplicationId
    8969634
  • Core Project Number
    R03AI113649
  • Full Project Number
    1R03AI113649-01A1
  • Serial Number
    113649
  • FOA Number
    PA-13-304
  • Sub Project Id
  • Project Start Date
    5/4/2015 - 9 years ago
  • Project End Date
    4/30/2017 - 7 years ago
  • Program Officer Name
    LU, KRISTINA
  • Budget Start Date
    5/4/2015 - 9 years ago
  • Budget End Date
    4/30/2016 - 8 years ago
  • Fiscal Year
    2015
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    5/4/2015 - 9 years ago

Immunogenicity of Moraxella catarrhalis vaccine candidates in children

? DESCRIPTION (provided by applicant): Immunogenicity of Moraxella catarrhalis vaccine candidates in children Abstract Moraxella catarrhalis (Mcat) is a bacterium causing more than 100 million cases of acute otitis media (AOM) in children worldwide and up to 3 million cases of acute exacerbations of chronic obstructive pulmonary disease in adults in the United States annually. There is no vaccine available to prevent Mcat infection. Our group has identified a subset of children who are stringently-defined otitis prone (sOP) that display low or absent antibody responses to most but not all vaccine candidate proteins of two leading bacteria responsible for AOM, nontypeable Haemophilus influenzae (NTHi) and Streptococcus pneumoniae (Spn). The immunologic mechanisms of these defects in sOP children are under intensive investigation in our laboratory (R01 DC08671). We propose to evaluate the age-dependent immunogenicity of and functional antibody response to 4 Mcat vaccine candidate proteins elicited by natural exposure to Mcat in sOP and non-otitis prone (NOP) children 6-36 months of age. Our central hypothesis is that detection of Mcat-specific functional antibodies is most effective in evaluating vaccine candidates with the greatest promise for clinical development. Therefore, we will (1) assess serum and mucosal antibody responses to Mcat nasopharyngeal (NP) colonization; (2) assess serum and mucosal antibody responses at onset of and after recovery from Mcat-caused AOM (3) analyze the correlative relationship between the serum and mucosal antibody responses and NP colonization and AOM rates; and (4) analyze the correlative relationship among the natural antibody responses to Mcat vaccine candidates. By comparing the immune responses between sOP and NOP children, we will identify those antigens that are highly immunogenic in sOP children. Use of these antigens in a vaccine, may lead to effectively raising the antibody response to a protective level against Mcat-caused recurrent AOM. We will determine those Mcat antigens that elicit synchronous antibody responses and therefore would be less likely to produce diminished antibody response caused by antigenic competition and interference in a multi-component vaccine. Overall, our study will help to identify Mcat antigens with the best potential in a multivalent vaccine to protect against AOM.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R03
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
    54224
  • Indirect Cost Amount
    32534
  • Total Cost
    86758
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:86758\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    VMD
  • Study Section Name
    Vaccines Against Microbial Diseases Study Section
  • Organization Name
    ROCHESTER GENERAL HOSPITAL (NY)
  • Organization Department
  • Organization DUNS
    043078385
  • Organization City
    ROCHESTER
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    146213001
  • Organization District
    UNITED STATES